nach oben

Erschienen in:

01.10.2007 | News item

Positive benefit-risk balance continues for glitazones – EMEA

Erschienen in: Reactions Weekly | Ausgabe 1/2007

Einloggen, um Zugang zu erhalten

Excerpt

The EMEA has completed its review of the benefits and risks of rosiglitazone and pioglitazone, concluding that the benefits of the antihyperglycaemic agents continue to outweigh the associated risks in the approved indication of type 2 diabetes mellitus.1 …

European Medicines Agency (EMEA).European Medicines Agency confirms positive benefit-risk balance for rosiglitazone and pioglitazone. Media Release: 18 Oct 2007. Available from: URL: http://www.emea.europa.eu

GlaxoSmirthKline.European Medicine Agency (EMEA) confirms positive Avandia benefit risk assessment. Media Release: 18 Oct 2007. Available from: URL: http://www.gsk.com

Titel: Positive benefit-risk balance continues for glitazones – EMEA
Publikationsdatum: 01.10.2007
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2007
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.2165/00128415-200711750-00003

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2007

Mirtazapine

Azathioprine

Rifampicin

Gentamicin interaction

Colchicine

General anaesthetics/rocuronium bromide